DESMOPLASTIC SMALL ROUND CELL TUMOR TREATMENT MARKET ANALYSIS

Desmoplastic Small Round Cell Tumor Treatment MarketSize and Trends

Desmoplastic Small Round Cell Tumor Treatment Market: Market Dynamics

Increasing incidence of genetic disorders and cancer is one of the major factors responsible for growth of the global desmoplastic small round cell tumor treatment market. According to a report published by Genetics Education Center, University of Kansas Medical Center 2012, 12% of the hospital admissions in the U.S. accounted for treatment of genetic causes in 2013. Moreover, according to the American Cancer Society 2017, the cancer occurring in stomach, small intestine, and gastrointestinal cavity are one of the most common of the rare cancer of the digestive systems. According to the Cancer Research UK 2016, rare cancers affects around 2 in 100,000 people. Additionally, increasing research and development to improve conditions of the patients suffering with rare cancers is also responsible to augment the market growth. For instance, the Memorial Sloan Kettering Cancer Center is conducting Phase 1 clinical trials to develop an intraperitoneal radiotherapy for patients suffering with desmoplastic small round cell tumors and is expected to complete its Phase 1 trial by April 2018.

Desmoplastic Small Round Cell Tumor Treatment Market: Market Taxonomy:

On the basis of treatment type, the global desmoplastic small round cell tumor treatment market is segmented into:

• Chemotherapy Drugs
  • Doxorubicin
  • Vincristine
  • Etoposide
  • Carboplatin
  • Cyclophaophamide
• Surgical Tumor Removal
• Radiotherapy

On the basis of end user, the global desmoplastic small round cell tumor treatment market is segmented into:

• Hospitals
• Cancer Treatment Centers
• Others